Home > News > First Clinical Validation Study on Nano-JETA Platform
May 6th, 2005
First Clinical Validation Study on Nano-JETA Platform
Abstract:
Acrongenomics Inc. a Research and Development company focusing in the field of nanobiotechnology has managed to reshape key IVD molecular applications such as PCR, ELISA and Real Time PCR through its Nano-JETA(TM) technology platform, by integrating nanotechnology into molecular biology.
Source:
businesswire
Bookmark:
| Related Links |
| Related News Press |
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Rice membrane extracts lithium from brines with greater speed, less waste October 3rd, 2025
Researchers develop molecular qubits that communicate at telecom frequencies October 3rd, 2025
Next-generation quantum communication October 3rd, 2025
"Nanoreactor" cage uses visible light for catalytic and ultra-selective cross-cycloadditions October 3rd, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||